Scarica l'app Stockscreener
7.21
1.23%
-0.09
Dopo l'orario di chiusura:
7.21
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.30
Aprire:
$7.3
Volume 24 ore:
963.05K
Relative Volume:
0.82
Capitalizzazione di mercato:
$672.07M
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-5.5462
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
+1.69%
1M Prestazione:
+10.24%
6M Prestazione:
+38.92%
1 anno Prestazione:
-50.28%
Intervallo 1D:
$7.20
$7.395
Intervallo di 1 settimana:
$6.99
$7.43
Portata 52W:
$3.76
$15.47
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Confronta MYGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.21 | 680.46M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Myriad Genetics Inc Stock Analysis and ForecastCapital Gains Strategies & High Profit Market Growth - earlytimes.in
Chart Watch: Why Myriad Genetics Inc stock could rally in 2025Weekly Investment Report & Low Drawdown Trading Strategies - moha.gov.vn
Will Breakout in GIC Housing Finance Limited Sustain Through Next WeekCapital Gains Strategies & Free Unmatched Market Gains - earlytimes.in
Myriad Genetics, Inc. $MYGN Stake Reduced by Camber Capital Management LP - MarketBeat
Discipline and Rules-Based Execution in MYGN Response - news.stocktradersdaily.com
Why Myriad Genetics (MYGN) Stock Is Up Today - Finviz
Myriad Genetics to Showcase Advances in Hereditary Cancer and MRD Testing at 2025 San Antonio Breast Cancer Symposium - Quiver Quantitative
Myriad Genetics (NASDAQ: MYGN) spotlights MRD and MyRisk data in 8 SABCS 2025 abstracts - Stock Titan
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings? - TradingView
Prudential Financial Inc. Has $1.82 Million Stock Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Fisher Asset Management LLC Purchases 219,607 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
What MACD trends signal for Myriad Genetics Inc. (MYD) stock2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Why Myriad Genetics Inc. stock appeals to analystsWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Can Myriad Genetics Inc. stock continue upward trendMarket Trend Review & Low Drawdown Trading Techniques - Newser
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? - MSN
Upcoming Virtual Meeting on December 11 Hosted by Craig-Hallum f - GuruFocus
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial - GlobeNewswire Inc.
1 Healthcare Stock with Promising Prospects and 2 We Question - Barchart.com
How Myriad Genetics Inc. stock benefits from strong dollarTrade Risk Assessment & Low Drawdown Investment Ideas - Newser
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today - Finviz
Myriad Genetics, Inc. $MYGN Stock Holdings Lifted by XTX Topco Ltd - MarketBeat
Myriad Genetics Outpaces Expectations But Faces Profit Challenges - Finimize
How Recent Developments Are Shaping the Myriad Genetics Investment Story - Yahoo Finance
UBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral Recommendation - MSN
Will Myriad Genetics Inc. stock return to pre crisis levelsJuly 2025 Outlook & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
Will Myriad Genetics Inc. stock attract more institutional investorsPortfolio Growth Summary & Real-Time Buy Signal Notifications - BỘ NỘI VỤ
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
How Myriad Genetics achieved fast, accurate, and cost-efficient document processing using the AWS open-source Generative AI Intelligent Document Processing Accelerator - Amazon Web Services (AWS)
Earnings Recap: Can Myriad Genetics Inc. stock double in next 5 yearsTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know - MSN
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - The Manila Times
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools By Investing.com - Investing.com Nigeria
Myriad Genetics partners to use AI to measure breast cancer risk - Seeking Alpha
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools - Investing.com
Clairity, Myriad Genetics, and MagView Collaborate to Enhance Breast Cancer Risk Assessment Tool - Quiver Quantitative
Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - marketscreener.com
Myriad Genetics (NASDAQ: MYGN), Clairity and MagView launch AI breast risk platform - Stock Titan
Myriad Genetics joins Forbes list of America's dream employers for 2026 - Traders Union
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Myriad Genetics Q3 2025 Earnings Preview - MSN
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Yahoo Finance
Can Myriad Genetics Inc. stock sustain market leadershipMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock nearing a technical breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
Will Myriad Genetics Inc. stock benefit from sector rotationJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):